Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

894results about How to "Avoid toxicity" patented technology

Combination methods of treating cancer

InactiveUS20070190022A1Dosage of each agent in a combination therapy can be reducedAntitumor effectBiocidePeptide/protein ingredientsAnticarcinogenOncology
The present invention relates to a method of treating cancer in a subject in need thereof, by administering to a subject in need thereof a first amount of a histone deacetylase (HDAC) inhibitor or a pharmaceutically acceptable salt or hydrate thereof, in a first treatment procedure, and a second amount of an anti-cancer agent in a second treatment procedure. The first and second amounts together comprise a therapeutically effective amount. The effect of the HDAC inhibitor and the anti-cancer agent may be additive or synergistic.
Owner:SLOAN KETTERING INST FOR CANCER RES +1

Enzyme treatment of foodstuffs for Celiac Sprue

Administering an effective dose of glutenase to a Celiac or dermatitis herpetiformis patient reduces levels of toxic gluten oligopeptides, thereby attenuating or eliminating the damaging effects of gluten.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV

Physiological tissue repair and functional organ regeneration by cultivation of regenerative stem cells in vivo and in situ

The present invention provides novel compositions and methods for pharmaceutical or nutraceutical use in an animal, preferably in a human. In one aspect, compositions and methods are provided for promoting cell growth, tissue repair and organ regeneration, preferably in vivo and in situ. The composition comprises a sterol compound dissolved in oil at a concentration at least 0.5% by weight. The compositions may be used in the treatment of various conditions caused by injury, diseases and aging. As shown clinically, the methodology disclosed in the present invention was used successfully to regenerate or clone a new organ through cultivation of regenerative stem cells in vivo and in situ.
Owner:XU RONGXIANG

Cytokine inhibitors

The present invention provides low molecular weight compounds useful as cytokine inhibitors, and compositions thereof. In particular, compounds of the invention are useful as anti-inflammatory agents. There are further provided methods for the preparation of such agents and their use in preventing or treating conditions mediated by cytokines such as arthritis.
Owner:CATALANO & CATALANO

Biomacromolecule interpenetrating polymer network hydrogel and preparation method thereof

The invention discloses a biomacromolecule interpenetrating polymer network hydrogel and a preparation method of the biomacromolecule interpenetrating polymer network hydrogel. The biomacromolecule interpenetrating polymer network hydrogel is formed by crosslinking two kinds of enzymes in a catalysis mode, one is a polysaccharide macromolecule network formed by crosslinking polysaccharide macromolecules with introduced phenolic hydroxyl groups in an oxidation mode as oxidase and hydrogen peroxide catalyze phenolic hydroxyl groups, and the other is a protein or polypeptide macromolecule network formed crosslinking protein or polypeptide containing amino acid residues as transferase catalyzes peptide bonds. The two networks interpenetrate each other and form the novel interpenetrating polymer network hydrogel without bonding of chemical bonds. No chemical crosslinking agent is used in the hydrogel, and the hydrogel has excellent biocompatibility and mechanical property, can be shaped like a dry or wet film, like porous sponge or fibers, and can serve as a contact lens, a medicine release carrier, a scaffold for tissue engineering or materials for tissue repair.
Owner:SOUTHEAST UNIV

Enzyme treatment of foodstuffs for Celiac Sprue

Administering an effective dose of glutenase to a Celiac or dermatitis herpetiformis patient reduces levels of toxic gluten oligopeptides, thereby attenuating or eliminating the damaging effects of gluten.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV

Controlled release immunomodulator compositions and methods for the treatment of otic disorders

Disclosed herein are compositions and methods for the treatment of otic disorders with immunomodulating agent compositions and formulations administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).
Owner:OTONOMY INC +1

Dosing regimen for Flaviviridae therapy

An anti-hepatitis C agent which is an anti-metabolite to the host and cannot be administered on a daily or chronic basis as is usual in anti-viral therapy (referred to below as an “anti-HCV anti-metabolite”), can be administered using a traditional anti-cancer dosing regimen (for example via intravenous or parenteral injection), over a period of one, two, three, four, five, six, or seven days followed by cessation of therapy until rebound of the viral load is noted. This dosing regimen runs counter to conventional antiviral experience, wherein effective agents are usually administered over at least fourteen days of sustained therapy, and typically on an indefinite daily basis.
Owner:PHARMASSET

Methods for the use of inhibitors of histone deacetylase as synergistic agents in cancer therapy

Improved methods for treatment of cancer are provided. The improvements include the administration of one or more synergistic agents, specifically inhibitors of histone deacetylase proteins and complexes. These synergistic agnets increase the effectiveness of radiation therapy and / or chemotherapies by increasing the sensitivity of tumor cells to treatment.
Owner:GEORGETOWN UNIV

Chimeric activators: quantitatively designed protein therapeutics and uses thereof

ActiveUS20110274658A1Reduced cell-activating propertyAvoid and reduce unwanted side effectObesity gene productsPeptide/protein ingredientsChimerin ProteinsApoptosis
Aspects of the invention provide methods for harnessing the potential of proteins that occur naturally (e.g., in humans) and that have serious but finite toxicity. Aspects of the invention relate to a quantitative systems-biological and structural approach to design a class Mof chimeric proteins that avoid the toxicity of protein drugs while retaining their desired activities. In particular, chimeric proteins containing a variant form of a natural protein fused to a targeting moiety may be administered to a subject to target a signal (e.g., induction of apoptosis) to particular cells without having a generalized toxic effect
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE

Organic waste water treatment process

Disclosed is a technique for processing organic waste water, including the following steps: (a) preprocession: pour the waste water into the micro electrolytic reducing pool where the iron-carbon micro electrolytic reaction occurs under the agtatering effect, add hydrogen peroxide into it to have. Fento oxidation, then the water enters into coagulation pool into which add NaOH and PAM; (b) anaerobe hydrolysis oxidation procession: power the organic waste water preprocessed into high effective anaerobe hydrolysis oxidation pool in which add into the TCBS reactor in which add into high effective compound microbe, making the water mix with the flowing-back mud with high density after denitrification. The invention can increase the biochemical of organic waste water, strengthen its resistance to poison and impact as well as the biological denitrification funcation, and making the waste water reach the national environment protection requirement by reducing the polluting load by steps.
Owner:何义亮 +1

Method of reducing or eliminating thrombus formation

InactiveUS7077860B2Facilitate subsequent loadingLong shelf lifeStentsPharmaceutical containersThrombosisThrombus
An implantable stent is coated with a material that attracts heparin and with which heparin forms a bond. The stent is exposed to a heparin containing solution just prior to implantation or is first implanted and then exposed to heparinized blood. As heparin becomes detached from the stent, the implantation site is exposed to heparin to restore an effective level and thereby prevent thrombosis.
Owner:ABBOTT CARDIOVASCULAR

Method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis

InactiveUS7247302B1Reduced and inhibited toxicityAvoid toxicityAntibody ingredientsImmunoglobulinsToxicityImmunotherapy
The present invention provides a method for inhibiting immunoglobulin-induced toxicity resulting from immunotherapy in a subject comprising administering an immunoglobulin or Ig fusion protein molecule to the subject, the immunoglobulin molecule having a variable region and a constant region, the immunoglobulin molecule being modified prior to administration by inactivation of at least a portion of the constant region.
Owner:BRISTOL MYERS SQUIBB CO

Compounds useful as anti-inflammatory agents

Disclosed are compounds useful in pharmaceutic compositions for treating diseases or pathological conditions involving inflammation such as chronic inflammatory diseases. Also disclosed are processes of making such compounds.
Owner:BOEHRINGER INGELHEIM PHARMA INC

Kinase Inhibitors for Preventing or Treating Pathogen Infection and Method of Use Thereof

The present invention provides compositions and methods of use thereof to prevent and / or treat pathogenic infection. In particular, the present invention provides the use of kinase inhibitors to inhibit kinases that involve in pathogen-host cell interactions that are associated with or cause pathogenic infections, therefore, to effectively prevent and / or treat pathogenic infections with far less likely to engender resistance as compared to conventional antibiotics and anti-viral drugs. The present invention further provides the use of kinase inhibitors for the treatment of acute pathogenic infections for a short period of time to avoid toxicities that may caused by long term use of these kinase inhibitors.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST +1

Compositions comprising amphotericin B, methods, and systems

InactiveUS20060025355A1Providing prophylaxisAvoid renalPowder deliveryBiocideCrystallinityAmphotericin B
A composition includes particles including at least about 95 wt % of amphotericin B, wherein the particles have a mass median diameter ranging from about 1.1 μm to about 1.9 μm. Another composition also includes particles including at least about 95 wt % of amphotericin B, wherein at least about 80 wt % of the particles have a geometric diameter ranging from about 1.1 μm to about 1.9 μm. Yet another composition includes particles including amphotericin B, wherein the particles have a mass median diameter less than about 1.9 μm, and wherein the amphotericin B has a crystallinity level of at least about 20%. Unit dosage forms, delivery systems, and methods may involve similar compositions.
Owner:NOVARTIS FARMA

Biological dehydrogenation preparation method of steroid drug intermediate

A biological dehydrogenation preparation method of steroid drug intermediate takes the formula (1) compound as a substrate, and adopts an arthrobacter simplex biological dehydrogenation method to obtain formula (2) compound; the special process comprises the following steps: smashing or dissolving the formula (1) compound with solvent, putting into a fermentation tank in which arthrobacter is cultivated for biotransformation, extracting, separating and refining, and drying to obtain dehydrogenated polymer, i.e. compound (2); and the dehydrogenation transformation rate can reach 70 to 90 percent.
Owner:TIANJIN JINYAO GRP

Microbial fertilizer-plant synbiotic composition preparation and method for preparing symbiotic preparation

The invention discloses a microbial fertilizer-plant synbiotic composition preparation and a method for preparing the synbiotic preparation. In the composition preparation, the plant synbiotic consists of probiotics, prebiotics and stabilizer; and bacillus forms zymotic fluid. The method for preparing the synbiotic preparation comprises the following steps: fermenting the probiotics; regulating bacteria amount; and preparing and homogenizing to obtain the product. Azotobacter, pralidoxime iodide and potassium bacteria in the preparation can increase soil nutrition, improve the fertilizer utilization rate and soil granule structures, promote the air permeability, water-retaining property and drainage, and overcome the defect of sunlight greenhouse continuous cropping; oligosaccharide prebiotics in the preparation can stimulate crops to improve resistance to pathogenic microorganisms, and promotes permanent planting and proliferation of the probiotics; the preparation can inhibit toxicity generated by bacteria, start self immunity system, eliminate diseases and remove evils, reduce bactericidal pesticide, has cold resistance, heat resistance, drought resistance, waterlogging resistance, saline and alkaline resistance, fertilizer damage resistance, chemical damage resistance and nutrition imbalance resistance, can promote plant root elongation and good development of capillary roots, and promote blooming and fruit yielding.
Owner:渭南德龙生物科技有限公司

Compounds for the treatment of CNS and amyloid associated diseases

Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing CNS and amyloid associated disease. Also described are methods, compounds, pharmaceutical compositions and kits for detecting, diagnosing, monitoring and treating or preventing CNS and amyloid associated disease.
Owner:BELLUS HEALTH (INT) LTD (CH)
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products